Equities

Viemed Healthcare Inc

Viemed Healthcare Inc

Actions
Health CareHealth Care Providers
  • Price (USD)7.46
  • Today's Change0.07 / 0.95%
  • Shares traded56.45k
  • 1 Year change+3.68%
  • Beta1.4735
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Viemed Healthcare Inc have a median target of 12.50, with a high estimate of 15.00 and a low estimate of 9.30. The median estimate represents a 67.56% increase from the last price of 7.46.
High101.1%15.00
Med67.6%12.50
Low24.7%9.30

Earnings history & estimates in USD

On Aug 07, 2024, Viemed Healthcare Inc reported 2nd quarter 2024 earnings of 0.04 per share.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate-2.58%
Viemed Healthcare Inc reported annual 2023 earnings of 0.25 per share on Mar 06, 2024.
Average growth rate+56.25%
More ▼

Revenue history & estimates in USD

Viemed Healthcare, Inc. had 2nd quarter 2024 revenues of 54.97m. This bettered the 53.80m estimate of the one analyst covering the company. This was 38.95% above the prior year's 2nd quarter results.
Average growth rate+6.28%
Viemed Healthcare, Inc. had revenues for the full year 2023 of 183.01m. This was 31.82% above the prior year's results.
Average growth rate+31.82%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.